{"id":3626,"date":"2026-07-16T18:07:33","date_gmt":"2026-07-16T18:07:33","guid":{"rendered":"https:\/\/indiamedicine.org\/?p=3626"},"modified":"2026-07-16T18:07:33","modified_gmt":"2026-07-16T18:07:33","slug":"india-uk-ceta-pharma-exports-rise-87-981m-fy27","status":"publish","type":"post","link":"https:\/\/indiamedicine.org\/?p=3626","title":{"rendered":"India-UK CETA: Pharma Exports to Rise 8.7% to $981M by FY27"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The landmark India-UK Comprehensive Economic Trade Agreement (CETA) came into effect on <strong>July 15, 2026<\/strong>, marking a new chapter for Indian pharmaceutical exports to Britain. The Pharmaceutical Export Promotion Council of India (Pharmexcil) projects that Indian pharma exports to the UK will grow by <strong>8.7%<\/strong>, reaching <strong>$981 million<\/strong> by the end of FY27.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">&#x1f4c8; India-UK CETA: Key Pharma Export Numbers<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The India-UK CETA, negotiated over several years, eliminates tariffs on <strong>99% of Indian exports<\/strong> entering the United Kingdom. For the pharmaceutical sector, this duty-free access is expected to provide a significant competitive advantage over non-FTA countries.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Projected pharma export growth:<\/strong> 8.7% to $981 million by FY27 \u2014 as reported by Pharmexcil (<a href=\"https:\/\/government.economictimes.indiatimes.com\" target=\"_blank\" rel=\"noopener\">ET Government<\/a>, July 16, 2026)<\/li>\n<li><strong>First-day impact:<\/strong> India exported over $140 million worth of goods to the UK on the first day of CETA implementation alone (<a href=\"https:\/\/businessupturn.com\" target=\"_blank\" rel=\"noopener\">Business Upturn<\/a>, July 15, 2026)<\/li>\n<li><strong>Tariff elimination:<\/strong> 99% of Indian exports now enter the UK duty-free, including all pharmaceutical products (<a href=\"https:\/\/www.moneycontrol.com\" target=\"_blank\" rel=\"noopener\">Moneycontrol<\/a>, July 2026)<\/li>\n<li><strong>Current baseline:<\/strong> Indian pharma exports to the UK stood at approximately $903 million in FY26 before the CETA boost<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">&#x1f52c; Regulatory Priorities for Pharma Under the FTA<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ahead of the July 15 rollout, the Indian pharmaceutical industry flagged several <strong>regulatory priorities<\/strong> that will determine how effectively the sector capitalises on the trade deal (<a href=\"https:\/\/economictimes.indiatimes.com\" target=\"_blank\" rel=\"noopener\">The Economic Times<\/a>, July 2026):<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mutual recognition of inspections:<\/strong> Indian manufacturers seek UK MHRA recognition of CDSCO GMP inspections, reducing duplication of audits<\/li>\n<li><strong>Data exclusivity provisions:<\/strong> Clarity on how the UK&#8217;s data exclusivity rules apply to Indian generic manufacturers post-Brexit<\/li>\n<li><strong>Supply chain security:<\/strong> Streamlined customs procedures for API and finished formulation shipments<\/li>\n<li><strong>Biosimilar market access:<\/strong> A clear regulatory pathway for Indian biosimilars entering the UK market through the Medicines and Healthcare products Regulatory Agency (MHRA)<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">&#x1f3ed; State-Level Impact: Telangana Leads the Way<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The southern state of <strong>Telangana<\/strong>, home to Hyderabad&#8217;s vibrant pharma and biotech cluster, is particularly well-positioned to benefit from the CETA. On the first day of implementation, export consignments were flagged off from Hyderabad, underscoring the region&#8217;s readiness to leverage tariff-free UK access (<a href=\"https:\/\/www.thehindu.com\" target=\"_blank\" rel=\"noopener\">The Hindu<\/a>, July 15, 2026).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Telangana accounts for approximately <strong>35% of India&#8217;s total pharmaceutical output<\/strong> and hosts major facilities of companies including <strong>Dr. Reddy&#8217;s, Aurobindo Pharma, Hetero, and Natco Pharma<\/strong> \u2014 all of which are expected to increase UK-bound shipments under the favourable tariff regime.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">&#x1f30d; Broader Context: India&#8217;s FTA-Driven Export Strategy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The India-UK CETA is part of a <strong>broader Indian trade strategy<\/strong> to secure preferential market access for its pharmaceutical sector, which is the world&#8217;s largest supplier of generic medicines by volume:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>April 2026:<\/strong> US granted tariff exemptions for generic medicines, strengthening Indian pharma&#8217;s position in its largest export market<\/li>\n<li><strong>January 2026:<\/strong> India-EU trade deal negotiations advanced with pharma as a key pillar (<a href=\"https:\/\/www.india-briefing.com\" target=\"_blank\" rel=\"noopener\">India Briefing<\/a>, January 2026)<\/li>\n<li><strong>Pharmexcil&#8217;s strategic roadmap:<\/strong> The council is hosting a &#8220;Chintan Shivir&#8221; in Ahmedabad to define a long-term roadmap leveraging these FTAs<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">&#x1f4a1; What This Means for Indian Generic Medicine Buyers<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">For international buyers and distributors of Indian generic medicines, the CETA brings several <strong>practical benefits<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lower barriers:<\/strong> Indian manufacturers exporting to the UK gain cost advantages that could translate into more competitive pricing across their global supply chains<\/li>\n<li><strong>Quality assurance:<\/strong> The MHRA-CDSCO regulatory alignment discussions could pave the way for mutual recognition of GMP certifications, making it easier for buyers to trust Indian manufacturing standards<\/li>\n<li><strong>Diversification:<\/strong> Increased UK market engagement means Indian pharma companies are expanding production capacity and quality systems \u2014 benefiting all export markets<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\">For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The landmark India-UK Comprehensive Economic Trade Agreement (CETA) came into effect on July 15, 2026, marking a new chapter for Indian pharmaceutical exports to Britain. The Pharmaceutical Export Promotion Council of India (Pharmexcil) projects that Indian pharma exports to the UK will grow by 8.7%, reaching $981 million by the end of FY27. &#x1f4c8; India-UK [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[42,48,49],"class_list":["post-3626","post","type-post","status-publish","format-standard","hentry","category-news","tag-cdsco","tag-generic-medicines","tag-indian-pharma","entry"],"_links":{"self":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3626"}],"version-history":[{"count":0,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3626\/revisions"}],"wp:attachment":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}